Escitalopram Oxalate Tablet, Film Coated
Product Images NDC 68645-520

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Escitalopram Oxalate (NDC 68645-520). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Legacy Pharmaceutical Packaging, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Escitalopram 10mg

Escitalopram Tablets, USP 10 mg tablet label showing the product name, strength, and dosage form. The label indicates 30 tablets per package and includes a blue and purple design highlight. It states the product is Rx Only and provides storage instructions, dispensing guidance, and warnings. Manufactured for Cipla USA Inc. and packaged by Legacy Pharmaceutical Packaging LLC, Earth City, MO.*

FDA Label Image

Escitalopram 20mg

Escitalopram Tablets USP 20 mg tablet label from Legacy Pharmaceutical Packaging, LLC. The label states 20 mg strength and quantity of 30 tablets. It includes usage instructions, storage conditions, warnings, and distribution information. The packaging indicates prescription use only and features a tablet image imprinted with 'IG' and '25I'.*

FDA Label Image

Image (Escitalopram Tabs Cipla Bottle 1)

A data table titled 'TABLE 1' showing the drug-placebo differences in cases of suicidality per 1000 patients treated with respect to age range groups: less than 18, 18-24, 25-64, and 65 or older. The table lists increased cases for patients under 25 and decreased cases for older age groups.*

FDA Label Image

Image (Escitalopram Tabs Cipla Bottle 2)

Table presenting treatment-emergent adverse reactions occurring with a frequency of 2% or more and greater than placebo in patients with Major Depressive Disorder treated with Escitalopram versus placebo. It categorizes adverse reactions by system, including autonomic nervous, central and peripheral nervous, gastrointestinal, general, psychiatric, respiratory, and urogenital disorders, with percentage incidence in Escitalopram (N=715) and placebo (N=592) groups.*

FDA Label Image

Image (Escitalopram Tabs Cipla Bottle 3)

A data table titled 'TABLE 3' presenting treatment-emergent adverse reactions for Escitalopram versus placebo in patients with Generalized Anxiety Disorder. The table lists adverse reaction categories, specific reactions, and observed percentages in Escitalopram (N=429) and placebo (N=427) groups, covering autonomic, nervous system, gastrointestinal, general, musculoskeletal, psychiatric, respiratory, and urogenital disorders.*

FDA Label Image

Image (Escitalopram Tabs Cipla Bottle 4)

A data table presenting the incidence of common adverse reactions in patients with major depressive disorder treated with Escitalopram Oxalate at daily doses of 10 mg and 20 mg compared to placebo. The table lists various adverse reactions and their percentages across placebo and two Escitalopram dose groups.*

FDA Label Image

Image (Escitalopram Tabs Cipla Bottle 5)

A data table titled 'Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials' comparing the percentage of adverse events for Escitalopram versus placebo. The table is divided by gender, reporting specific issues such as ejaculation disorder, decreased libido, impotence in males, and decreased libido and anorgasmia in females.*

FDA Label Image

Image (Escitalopram Tabs Cipla Bottle 6)

Chemical structure of Escitalopram Oxalate shown as a molecular diagram with labeled atoms and bonds, including the oxalate component (C2H2O4).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.